```html

Yellow Discoloration of the Sclera (Icteric Eyes)

What is Yellow Discoloration of the Sclera?

Yellow discoloration of the sclera – the white part of the eye – is medically known as icteric sclera or simply “yellow eyes.” The sclera becomes yellow when bilirubin, a yellow‑pigmented breakdown product of red blood cells, accumulates in the bloodstream and deposits in ocular tissues. While a slight yellow tint can be normal in newborns, persistent yellowing in children or adults usually signals an underlying health problem that needs evaluation.

Because the sclera is thin and highly vascular, it often reveals changes in blood chemistry earlier than skin. For this reason, yellow sclera is a valuable clinical clue that physicians use to assess liver function, hemolysis, and several metabolic disorders.

Common Causes

Below are the most frequently encountered conditions that can produce yellow sclera. They are grouped by the primary mechanism that raises bilirubin levels.

• Hepatocellular injury or dysfunction – hepatitis A, B, C, alcoholic liver disease, non‑alcoholic fatty liver disease (NAFLD), drug‑induced liver injury.
• Biliary obstruction – gallstones, cholangiocarcinoma, pancreatic head tumor, primary sclerosing cholangitis.
• Hemolytic anemia – hereditary spherocytosis, sickle cell disease, G6PD deficiency, autoimmune hemolysis.
• Genetic disorders of bilirubin metabolism – Gilbert’s syndrome (mild, intermittent jaundice) and Crigler‑Najjar syndrome (severe, often presents in infancy).
• Pancreatic diseases – pancreatic cancer or chronic pancreatitis causing compression of the common bile duct.
• Infectious diseases – leptospirosis, malaria, sepsis with liver involvement.
• Medication‑induced hyperbilirubinemia – high‑dose acetaminophen, certain antibiotics (e.g., rifampin), antiretrovirals, oral contraceptives.
• Neonatal physiologic jaundice – common in the first week of life due to immature liver enzyme systems.
• Obstructive or infiltrative liver disease – sarcoidosis, amyloidosis, metastatic cancer to the liver.
• Rare metabolic conditions – Rotor syndrome, Dubin‑Johnson syndrome (defects in bilirubin excretion).

Associated Symptoms

Yellow sclera rarely occurs in isolation. Look for other signs that point to the underlying cause:

• Skin changes – generalized yellowing (jaundice), itching (pruritus), dark urine, pale stools.
• Abdominal symptoms – right‑upper‑quadrant pain, fullness, nausea, loss of appetite.
• Systemic signs – fever, chills, night sweats (suggest infection or malignancy).
• Fatigue and weakness – common with liver disease and hemolysis.
• Dark-colored urine and light-colored stool – indicate conjugated bilirubin excretion problems.
• Bleeding tendencies – easy bruising, nosebleeds, or prolonged clotting time (decreased clotting factor production by the liver).
• Neurologic changes – confusion, asterixis (flapping tremor), or coma in severe liver failure (hepatic encephalopathy).
• Hemolysis clues – dark urine (hemoglobinuria), splenomegaly, pallor, rapid heart rate.

When to See a Doctor

Yellow sclera warrants medical attention, especially if any of the following are present:

• Yellowing that persists more than 2 weeks or progresses.
• Accompanying itching, dark urine, pale stools, or abdominal pain.
• Fever, chills, or unexplained weight loss.
• Signs of bleeding (easy bruising, gum bleeding, blood in stools).
• Confusion, drowsiness, or difficulty concentrating.
• History of liver disease, recent travel to malaria‑endemic areas, or new medications.
• In newborns: yellowing that spreads beyond the eyes, lasts longer than 2 weeks, or is accompanied by poor feeding or lethargy.

Diagnosis

Evaluation begins with a thorough history and physical exam, followed by targeted laboratory and imaging studies.

1. Laboratory tests

• Serum bilirubin (total and direct) – differentiates unconjugated (often hemolysis or genetic) from conjugated hyperbilirubinemia (obstructive or hepatocellular).
• Liver enzyme panel – ALT, AST, ALP, GGT; high ALT/AST suggests hepatocellular injury, while high ALP/GGT points to biliary obstruction.
• Complete blood count (CBC) – anemia, leukocytosis, or platelet abnormalities that may indicate hemolysis or infection.
• Hemolysis work‑up – haptoglobin, lactate dehydrogenase (LDH), reticulocyte count, peripheral smear.
• Viral hepatitis serologies – HBsAg, anti‑HBc, anti‑HCV.
• Coagulation profile – PT/INR; prolonged times suggest impaired liver synthetic function.
• Autoimmune markers – ANA, ASMA, anti‑LKM-1 when autoimmune hepatitis is suspected.

2. Imaging studies

• Abdominal ultrasound – first‑line for detecting gallstones, biliary duct dilatation, liver size, and masses.
• CT or MRI – better delineates pancreatic tumors, cholangiocarcinoma, and metastatic disease.
• Magnetic resonance cholangiopancreatography (MRCP) – non‑invasive view of the biliary tree.

3. Specialized tests

• Liver biopsy – when the cause remains unclear after non‑invasive studies.
• Genetic testing – to confirm Gilbert’s syndrome (UGT1A1 mutation) or Crigler‑Najjar.
• Serologic tests for malaria, leptospirosis, or other infections based on travel history.

Treatment Options

Treatment is directed at the underlying cause; the yellow sclera usually resolves when bilirubin levels normalize.

1. Hepatocellular disease

• Viral hepatitis – antiviral therapy (e.g., entecavir for HBV, direct‑acting antivirals for HCV).
• Alcoholic liver disease – complete abstinence, nutritional support, corticosteroids for severe alcoholic hepatitis.
• NAFLD/NASH – weight loss (7‑10 % of body weight), exercise, control of diabetes/lipids.

2. Biliary obstruction

• Endoscopic retrograde cholangiopancreatography (ERCP) with stone extraction or stent placement.
• Surgical removal of tumors or gallstones when appropriate.
• Antibiotics for cholangitis (e.g., ceftriaxone + metronidazole).

3. Hemolytic anemia

• Remove inciting drugs or treat infections.
• Specific therapies – e.g., corticosteroids for autoimmune hemolysis, hydroxyurea for sickle cell disease, or splenectomy in hereditary spherocytosis.
• Blood transfusion in severe anemia.

4. Genetic bilirubin disorders

• Gilbert’s syndrome – usually requires only reassurance; avoid fasting, severe stress, and certain drugs (e.g., protease inhibitors).
• Crigler‑Najjar type I – phototherapy in infancy, liver transplantation for definitive treatment.

5. Supportive & home measures

• Stay hydrated – adequate fluid intake helps the liver excrete bilirubin.
• Balanced diet rich in fruits, vegetables, lean protein, and healthy fats.
• Limit alcohol and avoid hepatotoxic over‑the‑counter medications (e.g., high‑dose acetaminophen).
• Use gentle eye hygiene; avoid rubbing the eyes, which can cause irritation.

Prevention Tips

While some causes (genetic syndromes) cannot be prevented, many risk factors are modifiable.

• Vaccinate against hepatitis A and B.
• Maintain a healthy weight – BMI < 25 kg/m² reduces NAFLD risk.
• Limit alcohol intake – ≤ 2 drinks per day for men, ≤ 1 for women.
• Practice safe medication use – follow dosing instructions, avoid mixing acetaminophen with alcohol.
• Use insect repellent and take prophylactic antimalarials when traveling to endemic regions.
• Screen for and manage diabetes, high cholesterol, and hypertension – these conditions accelerate liver disease.
• Regular medical check‑ups – especially if you have a family history of liver or blood disorders.
• For newborns – ensure early pediatric follow‑up; treat significant neonatal jaundice with phototherapy to prevent kernicterus.

Emergency Warning Signs

Key Take‑aways

Yellow discoloration of the sclera is a visual cue that bilirubin levels are elevated. While it can be benign in certain genetic conditions, it most often signals liver, biliary, or blood‑cell pathology that requires evaluation. Prompt recognition, appropriate laboratory testing, and targeted treatment of the underlying disorder are essential for resolution and for preventing serious complications such as liver failure, severe hemolysis, or neonatal kernicterus.

Always consult a healthcare professional if you notice new or persistent yellowing of the eyes, especially when accompanied by systemic symptoms.

---

Sources: Mayo Clinic, CDC, National Institutes of Health (NIH), World Health Organization (WHO), Cleveland Clinic, American Association for the Study of Liver Diseases (AASLD), peer‑reviewed journals (J Hepatology, Lancet Haematology).

```